Paper39796705
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives.
Savino A and 5 others. Cancers (Basel), 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives. Papers, record 39796705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796705
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N/A | Italian MUR Dipartimenti di Eccellenza 2023-2027 (l. 232/2016, art. 1, commi 314-337), | PubMed | ||
| N/A | Italian MUR PNRR PE06 "HEAL ITALIA - Health Extended Alliance for Innovative Therapies, Advanced Lab-research and Integrated Approaches of Precision Medicine" - Spoke 4 - Precision Diagnostics | PubMed | ||
| N/A | Italian MUR PRIN 2022 PNRR P2022H7JYZ "Non-invasive biological and molecular characteri-zation of autoimmune liver diseases and variant syndromes'. | PubMed |
Source PubMed
References218
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23408334 | Ipilimumab associated hepatitis: imaging and clinicopathologic findings. | Invest New Drugs | 2013 | https://conductscience.org/library/papers/23408334 | PubMed |
| 2 | 29371985 | Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. | Oncotarget | 2017 | https://conductscience.org/library/papers/29371985 | PubMed |
| 3 | 29289977 | Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. | Cancer Immunol Immunother | 2018 | https://conductscience.org/library/papers/29289977 | PubMed |
| 4 | 37567465 | Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: Case report and review of literature. | Clin Res Hepatol Gastroenterol | 2023 | https://conductscience.org/library/papers/37567465 | PubMed |
| 5 | 34115819 | Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. | PLoS One | 2021 | https://conductscience.org/library/papers/34115819 | PubMed |
| 6 | 31929981 | Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. | Can J Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/31929981 | PubMed |
| 7 | 38954360 | Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics. | Hepatol Int | 2024 | https://conductscience.org/library/papers/38954360 | PubMed |
| 8 | 33628621 | A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. | Oncoimmunology | 2021 | https://conductscience.org/library/papers/33628621 | PubMed |
| 9 | 34482313 | Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. | Eur J Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/34482313 | PubMed |
| 10 | 29403081 | Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. | Mod Pathol | 2018 | https://conductscience.org/library/papers/29403081 | PubMed |
| 11 | 37889520 | Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. | Hepatol Commun | 2023 | https://conductscience.org/library/papers/37889520 | PubMed |
| 12 | 31811095 | Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis. | BMJ Case Rep | 2019 | https://conductscience.org/library/papers/31811095 | PubMed |
| 13 | 36747017 | Immune checkpoint inhibitor combinations-current and emerging strategies. | Br J Cancer | 2023 | https://conductscience.org/library/papers/36747017 | PubMed |
| 14 | 36710655 | Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. | Immunotherapy | 2023 | https://conductscience.org/library/papers/36710655 | PubMed |
| 15 | 38372756 | Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis. | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38372756 | PubMed |
| 16 | 31656561 | Immunotherapy-related hepatitis: real-world experience from a tertiary centre. | Frontline Gastroenterol | 2019 | https://conductscience.org/library/papers/31656561 | PubMed |
| 17 | 35575047 | Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. | Cancer Rep (Hoboken) | 2022 | https://conductscience.org/library/papers/35575047 | PubMed |
| 18 | 28959504 | Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy. | Curr Radiol Rep | 2016 | https://conductscience.org/library/papers/28959504 | PubMed |
| 19 | 33927311 | Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. | Sci Rep | 2021 | https://conductscience.org/library/papers/33927311 | PubMed |
| 20 | 28749795 | Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management. | Am J Clin Oncol | 2018 | https://conductscience.org/library/papers/28749795 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42792706 | Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792706 | PubMed |
| 41589213 | Nivolumab and bevacizumab attenuate cisplatin-induced hepatic inflammation and apoptosis in rats. | Hepatol Forum | 2026 | https://conductscience.org/library/papers/41589213 | PubMed |
| 41394868 | Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/41394868 | PubMed |
| 40881884 | Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors. | Front Oncol | 2025 | https://conductscience.org/library/papers/40881884 | PubMed |
| 40868432 | Adolescent Survivors of Childhood Cancer: Biopsychosocial Challenges and the Transition from Survival to Quality of Life. | Children (Basel) | 2025 | https://conductscience.org/library/papers/40868432 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39796705
GET https://conductscience.org/api/papers/v1/39796705/references?page=2